| Literature DB >> 29844725 |
Yunbin Jiang1, Junzhi Wang2, Yunhong Wang3, Xiumei Ke4, Chuanhui Zhang3, Rongping Yang1.
Abstract
Several studies have reported the preventive or therapeutic effect of curcuminoids on chronic heart failure (CHF), but their application was limited due to low solubility and bioavailability. Our previous study indicates that self-emulsifying drug delivery system (SEDDS) improves the solubility and bioavailability of curcuminoids. Thus, the aim of this work was to investigate whether SEDDS could improve preventive effect of curcuminoids on CHF in rats. CHF model was were established by coronary artery ligation. Ninety rats were randomly and averagely divided into sham, model, low- or high-dose suspension or SEDDS of curcuminoids (66.68 or 266.68 mg/kg) groups. Hemodynamic indices were recorded by multipurpose polygraph. Serum oxidative indices, B-type natriuretic peptide (BNP) and heart weight index were determined by kits and electronic balance. Myocardial infarct area, ventricular dilatation degree and collagen volume fraction of myocardial interstitium were analyzed by Masson staining, picric acid and sirius red staining, light microscopy and image analysis system. Myocardial histopathology was observed by hematoxylin and eosin staining, Masson staining and light microscopy. Reduction of ventricular pump function, increase of BNP level and heart weight index, myocardial lipid peroxidation damage, myocardial infarction, myocardial fibrosis, and cardiac enlargement were detected or observed in model group relative to those in sham group. After treatment with suspension or SEDDS of curcuminoids, the above-mentioned pathological changes were obviously reversed relative to those in model group. Meanwhile, the ameliorative effect of SEDDS of curcuminoids was markedly better than that of suspension of curcuminoids. This work provides a valuable reference from pharmacodynamics for development of curcuminoids pharmaceutics.Entities:
Keywords: Chronic heart failure; Curcuminoids; Lipid peroxidation damage; Self-emulsifying drug delivery system; Ventricular pump function
Year: 2018 PMID: 29844725 PMCID: PMC5961756 DOI: 10.1016/j.jsps.2018.02.003
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Effect and difference of suspension and SEDDS of curcuminoids on hemodynamic indices in CHF rats.
| Group | HR (beats/min) | LVSP (mmHg) | LVEDP (mmHg) | +dp/dtmax (mmHg/s) | −dp/dtmax (mmHg/s) |
|---|---|---|---|---|---|
| Sham | 434.5 ± 18.2 | 172.5 ± 10.7 | 7.01 ± 0.91 | 4193 ± 312 | −4014 ± 314 |
| Model | 409.2 ± 17.2 | 107.0 ± 5.4 | 17.15 ± 1.71 | 2990 ± 339 | −2806 ± 352 |
| A1 | 411.8 ± 16.5 | 119.1 ± 12.1 | 12.17 ± 2.29 | 3445 ± 414 | −3303 ± 289 |
| A2 | 422.8 ± 22.1 | 125.6 ± 14.3 | 11.09 ± 1.87 | 3667 ± 459 | −3446 ± 346 |
| B1 | 421.4 ± 20.2 | 124.6 ± 12.3 | 11.5 ± 1.48 | 3639 ± 450 | −3410 ± 430 |
| B2 | 428.5 ± 19.5 | 148.0 ± 16.1 | 10.90 ± 2.18 | 3619 ± 382 | −3490 ± 323 |
HR: heart rate, LVSP: left ventricular systolic pressure, LVEDP: left ventricular end-diastolic pressure, +dp/dtmax: maximal rate of the increase of left ventricular pressure, −dp/dtmax: maximal rate of the decrease of left ventricular pressure; A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
p < .01, compared with those in sham group.
p < .05.
p < .01, compared with those in model group.
p < .05.
p < .01, compared with those in B2.
Effect and difference of suspension and SEDDS of curcuminoids on serum oxidative indices and BNP levels or activities in CHF rats.
| Group | SOD (U/mL) | GSH-Px (U/mL) | CAT (U/mL) | MDA (nmol/mL) | BNP (μg/L) |
|---|---|---|---|---|---|
| Sham | 138.2 ± 8.4 | 383.6 ± 14.5 | 5.64 ± 0.90 | 3.22 ± 0.86 | 10.27 ± 2.01 |
| Model | 97.1 ± 6.3 | 311.2 ± 12.6 | 2.29 ± 0.71 | 8.79 ± 0.95 | 44.20 ± 5.11 |
| A1 | 108.2 ± 7.3 | 321.9 ± 9.1 | 3.27 ± 0.73 | 7.20 ± 0.93 | 30.21 ± 4.24 |
| A2 | 118.5 ± 8.8 | 330.5 ± 11.8 | 3.75 ± 0.86 | 6.13 ± 0.78 | 29.27 ± 4.86 |
| B1 | 114.4 ± 8.2 | 328.9 ± 8.0 | 3.45 ± 0.56 | 7.10 ± 0.58 | 25.79 ± 4.48 |
| B2 | 124.2 ± 7.4 | 342.6 ± 9.8 | 4.40 ± 0.62 | 4.43 ± 0.83 | 19.21 ± 2.25 |
SOD: superoxide dismutase, GSH-Px: glutathione peroxidase, CAT: catalase, MDA: malonaldehyde, BNP: B-type natriuretic peptide; A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
p < .01, compared with those in sham group.
p < .05.
p < .01, compared with those in model group.
p < .05.
p < .01, compared with those in B2.
Fig. 1Effect and difference of suspension and SEDDS of curcuminoids on heart macroscopic morphology in CHF rats (arrows point to infarction region); A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
Fig. 2Effect and difference of suspension and SEDDS of curcuminoids on heart microcosmic morphology in CHF rats (Masson staining, arrows point to infarction region); A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
Effect and difference of suspension and SEDDS of curcuminoids on myocardial infarct area and ventricular dilatation degree in CHF rats.
| Group | MIS (%) | LVIL (mm) | LVC (mm) | LVID (mm) |
|---|---|---|---|---|
| Sham | 0.00 ± 0.00 | 0.00 ± 0.00 | 19.70 ± 2.44 | 4.92 ± 0.53 |
| Model | 37.48 ± 2.43 | 10.69 ± 0.78 | 31.30 ± 1.90 | 9.78 ± 0.81 |
| A1 | 31.25 ± 3.03 | 8.27 ± 0.92 | 27.52 ± 2.15 | 8.49 ± 0.66 |
| A2 | 28.61 ± 2.02 | 7.78 ± 0.49 | 26.27 ± 2.57 | 7.83 ± 0.87 |
| B1 | 29.51 ± 2.08 | 7.62 ± 0.60 | 26.41 ± 1.86 | 8.21 ± 0.49 |
| B2 | 25.58 ± 3.04 | 6.75 ± 0.51 | 24.11 ± 2.30 | 6.69 ± 0.58 |
MIS: myocardial infarct size, LVIL: infarct length of left ventricle, LVC: circumference of left ventricle, LVID: inner diameter of left ventricle; A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
p < .01, compared with those in sham group.
p < .05.
p < .01, compared with those in model group.
p < .05.
p < .01, compared with those in B2.
Fig. 3Effect and difference of suspension and SEDDS of curcuminoids on CVF of myocardial interstitium in CHF rats (picric acid and sirius red staining, magnification ×200); A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
Fig. 4Effect and difference of suspension and SEDDS of curcuminoids on myocardial histopathology in CHF rats (hematoxylin and eosin staining, magnification ×400); A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.
Fig. 5Effect and difference of suspension and SEDDS of curcuminoids on myocardial histopathology in CHF rats (Masson staining, magnification ×400); A1: low-dose suspension of curcuminoids, A2: high-dose suspension of curcuminoids, B1: low-dose SEDDS of curcuminoids, B2: high-dose SEDDS of curcuminoids.